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Background: Limited data are currently available on the performance of second generation DES for treatment of bifurcation lesions. We investigate 
the long-term clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES).
Methods: The RESOLUTE All Comers trial is a randomized, multicenter, non-inferiority trial with minimal inclusion criteria. Patients were randomly 
assigned to percutaneous coronary artery interventions with either zotarolimus or everolimus eluting stents. A total of 2223 patients were followed 
up in the present study, 1838 patients underwent percutaneous coronary intervention in non-bifurcation and 385 in bifurcation lesions. The 
composite endpoints of major adverse cardiac events (MACE), target lesion failure (TLF), definite or probable and definite probable or possible 
stent thrombosis were assessed. In addition cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR) were observed and 
compared at 2-year follow-up.
Results: At 2-year follow-up, TLF rate was higher in the bifurcation lesion group compared to non-bifurcation lesion group (13.7% vs 9.7%, 
p=0.021) with a trend toward a higher rate of MACE (15.0% vs 11.5%, p=0.059), overall MI (7.2% vs 4.7%, p=0.058) and a higher rate of peri-
procedural MI (6.5% vs 3.4%, p=0.009). No differences were observed in terms of cardiac deaths (2.0% vs 2.3%, p=0.853), TLR (6.0% vs 4.7%, 
p=0.299) and in the composite endpoints of definite or probable stent thrombosis (1.8% vs 1.6%, p=0.661), and definite probable or possible stent 
thrombosis (3.1% vs 3.0%, p=0.870) irrespectively of stent type.
Conclusion: Treatment of bifurcation and non-bifurcation lesions with second generation DES showed similar rates of cardiac death, TLR, and stent 
thrombosis. However bifurcations remained associated with an overall higher rate of events.
